Wednesday, December 10, 2014 12:36:07 PM
"We are very excited about this novel, enabling antibody-drug conjugate technology that we intend to use for the targeted delivery of MCT-485 as well as other drugs", said W. Gerald Newmin, Chairman and Chief Executive Officer of MultiCell Technologies. "We also plan to explore other therapeutic indications, other drug combinations, and to aggressively seek partnerships with larger pharmaceutical and biotechnology companies who are interested in using ADC technology to help facilitate the targeted delivery of their drugs", stated Mr. Newmin.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM